News

DrugDev to Promote Adoption of Innovative Technologies to Advance Clinical Study Efficiency at Prestigious Pharma and Biotech Industry Conferences in Q4

 DrugDev, creators of the DrugDev Spark™ unified suite of clinical solutions, to share best practices gained from 2,000+ clinical studies at Site Solutions Summit, SOCRA, and Linking Leaders

Philadelphia, PA and London, UK – Executives and subject matter experts from DrugDev, a QuintilesIMS company, who enable the world’s most progressive pharma and biotech organizations to do more clinical trials will share best practices learned from over 2,000 clinical trials at top pharma and biotech events in Q4.

DrugDev will demonstrate DrugDev Spark™, the world’s first unified clinical operations suite which improves global trials from planning through closeout, with proven solutions including site selection and feasibility (featuring the DrugDev Golden Number universal identifier), site activation, eConsent, site payments, LMS, site engagement, document management and more.

2017 Global Site Solutions Summit | October 5-8, Boca Raton – Summit faculty member Melissa “Liss” Easy, DrugDev founder and President, SiteStart will apply her passion for improving the site-patient relationship by judging entrants for the SCRS Site Patient Recruitment Innovation Award. Presentations will take place October 7, and the winner will be announced October 8. Liss also will participate in a panel discussion, “Stand Out in Site Identification,” on October 7, 3:00-4:00 pm.  Liss founded DrugDev to bring sponsors, sites and patients together through better technology-driven solutions and services, and more open communication. Her honors include being named to the PharmaVOICE 100 and winning the Partnerships in Clinical Trials Woman of the Year award. And, see a demonstration of DrugDev Spark at Booth 406.

2017 Society of Clinical Research Associates (SOCRA), | October 6-8, Orlando – Dr. Susan Brink, eConsent visionary and DrugDev Strategic Advisor, Patient Solutions will present “Considerations When Implementing e-Consent.” Investigative sites are the linchpins in the adoption of eConsent. Dr. Brink’s presentation, part of the “Data Management / EDC” track, takes place October 6, 4:15-5:00 pm. Attendees will learn about:

• FDA guidelines for eConsent and components that address the guidelines
• Elements of eConsent which investigators report are especially helpful, including version tracking, electronic handwritten signatures, and availability on a tablet device
• The importance of site preparation and attention to the needs of the site staff
• Lessons learned through implementation of eConsent at clinical sites for over 100 trials. Specific examples of actions that can be taken to aid sites during initial stages of adoption will be shared

Clinical operations executives may also connect with DrugDev at additional meetings:

• Linking Leaders |October 6, San Francisco and November 9, Philadelphia
• Arena Outsourcing in Clinical Trials Canada | October 18-19, Toronto
• Partnerships in Clinical Trials Europe |November 28-29, Amsterdam, The Netherlands

To schedule a demo of DrugDev Spark – the world’s first unified clinical operations suite –  email solutions@drugdev.com.

About DrugDev

DrugDev, a QuintilesIMS company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience.  DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.